nach oben

European Radiology

Erschienen in:

21.02.2023 | Nuclear Medicine

The added value of [⁶⁸Ga]Ga-DOTA-FAPI-04 PET/CT in pancreatic cancer: a comparison to [¹⁸F]F-FDG

verfasst von: Qiufang Liu, Si Shi, Shuai Liu, Xiaoping Xu, Silong Hu, Ji Zhang, Chunmei Wang, Xianjun Yu, Shaoli Song

Erschienen in: European Radiology | Ausgabe 7/2023

Einloggen, um Zugang zu erhalten

Abstract

Objectives

We aimed to compare the diagnostic and prognostic performance of [⁶⁸Ga]Ga-DOTA-FAPI-04 and [¹⁸F]FDG PET/CT in pancreatic cancer.

Methods

This single-center retrospective study enrolled 51 patients who underwent [⁶⁸Ga]Ga-DOTA-FAPI-04 and [¹⁸F]FDG PET/CT. The final diagnosis on PET/CT images was verified by histopathology or 1-year follow-up. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of [¹⁸F]FDG and [⁶⁸Ga]Ga-DOTA-FAPI-04 PET/CT were calculated to compare the diagnostic efficacy. Progression-free survival (PFS) was the endpoint for the survival analysis. Twenty-six patients were eligible for the Kaplan–Meier survival analysis using a log-rank test. And multivariate analysis including age, sex, stage, CA199 level, and SUV_max of [¹⁸F]FDG and [⁶⁸Ga]Ga-DOTA-FAPI-04 was also performed. Two-tailed p < 0.05 was considered statistically significant.

Results

[⁶⁸Ga]Ga-DOTA-FAPI-04 showed a higher sensitivity than [¹⁸F]FDG for detecting primary tumor (100% vs. 95.0%), metastatic lymph nodes (96.2% vs. 61.5%), and distant metastases (100% vs. 84.0%) (p < 0.0001, respectively). For [⁶⁸Ga]Ga-DOTA-FAPI-04, the tumor-to-liver background ratio (TLBR) of liver metastases was higher (5.7 ± 3.2 vs. 3.2 ± 1.3, p < 0.0001). Furthermore, SUV_max > 14.9 on [⁶⁸Ga]Ga-DOTA-FAPI-04 was significantly associated with PFS rates (chi-square = 12.05, p = 0.001). The Cox regression analysis showed that SUV_max of [⁶⁸Ga]Ga-DOTA-FAPI-04 was an independent prognostic factor for PFS (p = 0.001; hazard ratio, 8.877).

Conclusions

[⁶⁸Ga]Ga-DOTA-FAPI-04 PET/CT showed a higher sensitivity and accuracy than [¹⁸F]FDG PET/CT in diagnosing pancreatic cancer and might have an independent prognostic value for pancreatic cancer patients.

Key Points

• [⁶⁸Ga]Ga-DOTA-FAPI-04 PET/CT had a higher sensitivity and accuracy in detecting primary tumors, metastatic lymph nodes, and distant metastases than [¹⁸F]FDG PET/CT.

• SUV_max > 14.9 on [⁶⁸Ga]Ga-DOTA-FAPI-04 PET/CT before chemotherapy was significantly associated with progress-free status rates (chi-square = 12.05, p = 0.001) in pancreatic cancer patients.

Tempero MA (2019) NCCN guidelines updates: pancreatic cancer. J Natl Compr Canc Netw 17:603–605PubMed

Arnold M, Rutherford MJ, Bardot A et al (2019) Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol 20:1493–1505CrossRefPubMedPubMedCentral

Siegel RL (2020) Miller KD (2020) Cancer statistics. CA Cancer J Clin 70:7–30CrossRefPubMed

Scialpi M, Reginelli A, D’Andrea A et al (2016) Pancreatic tumors imaging: an update. Int J Surg 1:S142-155CrossRef

Daamen LA, Groot VP, Goense L et al (2018) The diagnostic performance of CT versus FDG PET-CT for the detection of recurrent pancreatic cancer: a systematic review and meta-analysis. Eur J Radiol 106:128–136CrossRefPubMed

Wartski M, Sauvanet A (2019) ¹⁸F-FDG PET/CT in pancreatic adenocarcinoma: a role at initial imaging staging? Diagn Interv Imaging 100:735–741CrossRefPubMed

Biffi G, Tuveson DA (2021) Diversity and biology of cancer-associated fibroblasts. Physiol Rev 101:147–176CrossRefPubMed

Sahai E, Astsaturov I (2020) A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer 20:174–186CrossRefPubMedPubMedCentral

Kratochwil C, Flechsig P, Lindner T et al (2019) (68)Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med 60:801–805CrossRefPubMedPubMedCentral

10.

Chen H, Pang Y, Li J et al (2022) Comparison of [(68)Ga]Ga-FAPI and [(18)F]FDG uptake in patients with gastric signet-ring-cell carcinoma: a multicenter retrospective study. Eur Radiol 33:1329–1341CrossRefPubMed

11.

Chen S, Chen Z, Zou G et al (2022) Accurate preoperative staging with [(68)Ga]Ga-FAPI PET/CT for patients with oral squamous cell carcinoma: a comparison to 2-[(18)F]FDG PET/CT. Eur Radiol 32:6070–6079CrossRefPubMed

12.

Coto-Llerena M, Ercan C, Kancherla V et al (2020) High expression of FAP in colorectal cancer is associated with angiogenesis and immunoregulation processes. Front Oncol 10:979CrossRefPubMedPubMedCentral

13.

Hessmann E, Buchholz SM, Demir IE et al (2020) Microenvironmental determinants of pancreatic cancer. Physiol Rev 100:1707–1751CrossRefPubMed

14.

Elyada E, Bolisetty M, Laise P et al (2019) Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discov 9:1102–1123CrossRefPubMedPubMedCentral

15.

Yin Z, Dong C, Jiang K et al (2019) Heterogeneity of cancer-associated fibroblasts and roles in the progression, prognosis, and therapy of hepatocellular carcinoma. J Hematol Oncol 12:1–9CrossRef

16.

Röhrich M, Naumann P, Giesel FL et al (2020) Impact of (68)Ga-FAPI-PET/CT imaging on the therapeutic management of primary and recurrent pancreatic ductal adenocarcinomas. J Nucl Med 62:779–786CrossRefPubMed

17.

Zhang Z, Jia G, Pan G et al (2022) Comparison of the diagnostic efficacy of (68) Ga-FAPI-04 PET/MR and (18)F-FDG PET/CT in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging 49:2877–2888CrossRefPubMed

18.

Xu D, Wang J, Liu T et al (2021) Quantitative definitions of pain, CA19-9, and tumor size as high-risk features of resectable pancreatic cancer: a single-center retrospective cohort study. Gland Surg 10:770–779CrossRefPubMedPubMedCentral

19.

Wu Z, Zhao P, Wang Z et al (2022) Adjusting CA19-9 values with clinical stage and bilirubin to better predict survival of resectable pancreatic cancer patients: 5-year-follow-up of a single center. Front Oncol 12

20.

Pang Y, Zhao L (2021) Comparison of (68)Ga-FAPI and (18)F-FDG uptake in gastric, duodenal, and colorectal cancers. Radiology 298:393–402CrossRefPubMed

21.

Fan C, Guo W, Su G et al (2021) widespread metastatic gastric signet-ring cell carcinoma shown by 68Ga-FAPI PET/CT. Clin Nucl Med 46:e78–e79CrossRefPubMed

22.

Guo W, Pang Y, Yao L et al (2020) Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [(68)Ga]Ga-FAPI-04 PET/CT versus MRI and [(18)F]-FDG PET/CT. Eur J Nucl Med Mol Imaging 48:1604–1617CrossRefPubMed

23.

Pang Y, Zhao L, Shang Q et al (2021) Positron emission tomography and computed tomography with [(68)Ga]Ga-fibroblast activation protein inhibitors improves tumor detection and staging in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging 49:1322–1337CrossRefPubMed

24.

Sandberg TP, Stuart M, Oosting J et al (2019) Increased expression of cancer-associated fibroblast markers at the invasive front and its association with tumor-stroma ratio in colorectal cancer. BMC Cancer 19:284CrossRefPubMedPubMedCentral

25.

Liao Y, Ni Y, He R et al (2013) Clinical implications of fibroblast activation protein-α in non-small cell lung cancer after curative resection: a new predictor for prognosis. J Cancer Res Clin Oncol 139:1523–1528CrossRefPubMed

26.

Lo A, Li CP, Buza EL et al (2017) Fibroblast activation protein augments progression and metastasis of pancreatic ductal adenocarcinoma. JCI Insight 2:e92232CrossRefPubMedPubMedCentral

27.

Mao X, Xu J, Wang W et al (2021) Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer 20:131CrossRefPubMedPubMedCentral

28.

Altmann A, Haberkorn U, Siveke J (2021) The latest developments in imaging of fibroblast activation protein. J Nucl Med 62:160–167CrossRefPubMed

29.

Luo Y, Pan Q, Zhang W et al (2020) Intense FAPI uptake in inflammation may mask the tumor activity of pancreatic cancer in 68Ga-FAPI PET/CT. Clin Nucl Med 45:310–311CrossRefPubMed

30.

Bulle A, Lim KH (2020) Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer. Signal Transduct Target Ther 5:1–12

31.

Ogawa Y, Masugi Y (2021) Three distinct stroma types in human pancreatic cancer identified by image analysis of fibroblast subpopulations and collagen. Clin Cancer Res 27:107–119CrossRefPubMed

32.

Saluja A, Maitra A (2019) Pancreatitis and pancreatic cancer. Gastroenterology 156:1937–1940CrossRefPubMed

Titel: The added value of [68Ga]Ga-DOTA-FAPI-04 PET/CT in pancreatic cancer: a comparison to [18F]F-FDG
verfasst von: Qiufang Liu
Si Shi
Shuai Liu
Xiaoping Xu
Silong Hu
Ji Zhang
Chunmei Wang
Xianjun Yu
Shaoli Song
Publikationsdatum: 21.02.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: European Radiology / Ausgabe 7/2023
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-023-09445-y

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

The added value of [⁶⁸Ga]Ga-DOTA-FAPI-04 PET/CT in pancreatic cancer: a comparison to [¹⁸F]F-FDG